Skip to main content
. 2021 Apr 19;19(4):e3001201. doi: 10.1371/journal.pbio.3001201

Fig 7. Weight loss, viremia, and testes size in IFNAR−/− mice post-ZIKVPRVABC59 challenge.

Fig 7

(A) Weight loss of ZIKVPRVABC59-challenged IFNAR−/− mice (n = 3–5 mice per group). (B) Viremia post-ZIKVPRVABC59 challenge (n = 4–5 mice per group). (C) Testes size (height × width) and representative images of testes from vaccinated mice post-ZIKVPRVABC59 challenge compared with testes of not vaccinated, PBS-injected control mice and naïve (uninfected, healthy control) mice. Asterisk indicates significant difference from mice that received PBS injections instead of vaccination prior to ZIKVPRVABC59 challenge (Kruskal–Wallis test, p < 0.05). (D) Vaccine safety test displays the mean testis size of mice infected with CpG_max or UpA_max mutant viruses (n = 6 mice per group, testes harvested on day 49 postvaccination) compared with testes size of naïve mice (n = 3) without subsequent challenge. (E) qRT-PCR of ZIKV RNA in testes of mice from D and mice infected with ZIKVPRVABC59 for 48 days as positive control. Bars represent the mean Ct values normalized for RPL13A housekeeping RNA. The numerical values for this figure are available in S1 Data. Ct, cycle threshold; qRT-PCR, real-time quantitative reverse transcription PCR; SCR, scrambled control virus; WT, wild-type; ZIKV, Zika virus.